Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects

Thomas J Raife1, Donna J Lager

  • 1Department of Pathology, University of Iowa, Iowa City 52242, USA. thomas-raife@uiowa.edu

Abstract

Insights

A small group of cancer patients developed kidney failure and thrombotic microangiopathy (TM) without typical blood disorder signs. This renal TM may be missed if not specifically looked for in these patients.

Area of Science:

  • Nephrology
  • Oncology
  • Pathology

Background:

  • Thrombotic microangiopathy (TM) typically presents with hemolytic anemia and thrombocytopenia.
  • Renal involvement in TM can lead to progressive renal failure.

Observation:

  • Six patients undergoing cancer treatment developed progressive renal failure.
  • These patients exhibited renal thrombotic microangiopathy (TM) on biopsy.
  • Characteristic hematologic disturbances of TM were notably absent.

Findings:

  • Patients presented with slowly evolving uremia following radiation and/or chemotherapy.
  • Renal biopsies revealed TM alongside tubulointerstitial scarring, indicating acute and chronic injury.
  • Plasma exchange did not improve renal function in two patients.
  • Angiotensin-converting enzyme inhibitors stabilized or mildly improved renal function in three hypertensive patients.

Implications:

  • A subset of cancer patients can develop renal TM without overt hematologic abnormalities.
  • The diagnosis of renal TM may be overlooked in the absence of typical laboratory findings.
  • This highlights the importance of renal biopsy in diagnosing unexplained renal failure in cancer patients.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...